Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nathaniel Katz

Showing results (31-40 of 67) with videos related to

Pageof 7
Sort By:
Pain|June 11, 2013
Efficacy, safety, and tolerability of fulranumab, an anti-nerve growth factor antibody, in the treatment of patients with moderate to severe osteoarthritis painPanna Sanga, Nathaniel Katz, Elena Polverejan, et al.
The Clinical Journal of Pain|August 22, 2007
Internet surveillance: content analysis and monitoring of product-specific internet prescription opioid abuse-related postingsStephen F Butler, Synne Wing Venuti, Christine Benoit, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 18, 2016
Long-Term Safety and Efficacy of Fulranumab in Patients With Moderate-to-Severe Osteoarthritis Pain: A Phase II Randomized, Double-Blind, Placebo-Controlled Extension StudyPanna Sanga, Nathaniel Katz, Elena Polverejan, et al.
Pain Medicine (Malden, Mass.)|December 17, 2009
Estimating attractiveness for abuse of a not-yet-marketed "abuse-deterrent" prescription opioid formulationStephen F Butler, Ryan Black, Jill M Grimes Serrano, et al.
Journal of Addiction Medicine|July 20, 2011
Illustration of a statistical process control approach to regional prescription opioid abuse surveillanceJames C Benneyan, Albert Villapiano, Nathaniel Katz, et al.
Journal of Managed Care & Specialty Pharmacy|June 27, 2017
Burden of Alcohol Abuse or Dependence Among Long-Term Opioid Users with Chronic Noncancer PainPamela B Landsman-Blumberg, Nathaniel Katz, Kavita Gajria, et al.
Pain Reports|February 2, 2019
NEO6860, modality-selective TRPV1 antagonist: a randomized, controlled, proof-of-concept trial in patients with osteoarthritis knee painPierre Arsenault, Dan Chiche, William Brown, et al.
Pain Medicine (Malden, Mass.)|December 17, 2009
Measuring attractiveness for abuse of prescription opioidsStephen F Butler, Kathrine C Fernandez, Alan Chang, et al.
Journal of Managed Care & Specialty Pharmacy|September 30, 2020
Direct Costs of Opioid Abuse in an Insured Population in the United StatesAlan G White, Howard G Birnbaum, Milena N Mareva, et al.
Current Medical Research and Opinion|January 30, 2007
A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back painNathaniel Katz, Richard Rauck, Harry Ahdieh, et al.
Pageof 7

Showing results (31-40 of 67) with videos related to

Sort By:
Pageof 7
Pain|June 11, 2013
Efficacy, safety, and tolerability of fulranumab, an anti-nerve growth factor antibody, in the treatment of patients with moderate to severe osteoarthritis painPanna Sanga, Nathaniel Katz, Elena Polverejan, et al.
The Clinical Journal of Pain|August 22, 2007
Internet surveillance: content analysis and monitoring of product-specific internet prescription opioid abuse-related postingsStephen F Butler, Synne Wing Venuti, Christine Benoit, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 18, 2016
Long-Term Safety and Efficacy of Fulranumab in Patients With Moderate-to-Severe Osteoarthritis Pain: A Phase II Randomized, Double-Blind, Placebo-Controlled Extension StudyPanna Sanga, Nathaniel Katz, Elena Polverejan, et al.
Pain Medicine (Malden, Mass.)|December 17, 2009
Estimating attractiveness for abuse of a not-yet-marketed "abuse-deterrent" prescription opioid formulationStephen F Butler, Ryan Black, Jill M Grimes Serrano, et al.
Journal of Addiction Medicine|July 20, 2011
Illustration of a statistical process control approach to regional prescription opioid abuse surveillanceJames C Benneyan, Albert Villapiano, Nathaniel Katz, et al.
Journal of Managed Care & Specialty Pharmacy|June 27, 2017
Burden of Alcohol Abuse or Dependence Among Long-Term Opioid Users with Chronic Noncancer PainPamela B Landsman-Blumberg, Nathaniel Katz, Kavita Gajria, et al.
Pain Reports|February 2, 2019
NEO6860, modality-selective TRPV1 antagonist: a randomized, controlled, proof-of-concept trial in patients with osteoarthritis knee painPierre Arsenault, Dan Chiche, William Brown, et al.
Pain Medicine (Malden, Mass.)|December 17, 2009
Measuring attractiveness for abuse of prescription opioidsStephen F Butler, Kathrine C Fernandez, Alan Chang, et al.
Journal of Managed Care & Specialty Pharmacy|September 30, 2020
Direct Costs of Opioid Abuse in an Insured Population in the United StatesAlan G White, Howard G Birnbaum, Milena N Mareva, et al.
Current Medical Research and Opinion|January 30, 2007
A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back painNathaniel Katz, Richard Rauck, Harry Ahdieh, et al.
Pageof 7